Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 460 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
460 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with locally advanced, recurrent, or metastatic non-small cell lung cancer (both non-squamous and squamous), whose tumors have cMET overexpression or MET aberrations, including patients previously treated with standard therapies and both EGFR mutation-positive and -negative subgroups. Patients receive MYTX-011, a cMET-directed antibody-drug conjugate delivering MMAE, with dose escalation and expansion in molecularly defined cohorts.
ClinicalTrials.gov ID: NCT05652868
HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic solid tumors harboring HER2 aberrations (mutations, amplification, or overexpression) or EGFR exon 20 insertions who have progressed on standard therapies, and treats them with YH42946, an oral tyrosine kinase inhibitor targeting mutant HER2 and EGFR exon 20 insertions.
ClinicalTrials.gov ID: NCT06616766
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors linked to COX2-mediated immunosuppression who have exhausted standard therapies, including specific expansion cohorts for sarcoma, pancreatic cancer, NSCLC without driver mutations, microsatellite stable/low colorectal cancer, and head and neck squamous cell carcinoma. Patients receive OKN4395, an oral triple antagonist of EP2, EP4, and DP1 prostanoid receptors, as monotherapy or in combination with pembrolizumab.
ClinicalTrials.gov ID: NCT06789172
HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR (including classical, atypical, exon 20 insertion, and resistance mutations) and/or HER2 kinase domain mutations who have received standard therapies, testing the investigational oral agent BH-30643, a mutant-selective OMNI-EGFR inhibitor targeting a broad spectrum of EGFR and HER2 mutations. Patients must have measurable disease, good performance status, and no significant comorbidities or prior ILD.
ClinicalTrials.gov ID: NCT06706076
HealthScout AI summary: This trial enrolls adults with selected advanced solid tumors—including NSCLC, renal cell carcinoma, melanoma, platinum-resistant ovarian cancer, nasopharyngeal carcinoma, and triple negative breast cancer—who have progressed after specific prior therapies, to evaluate the safety and dosing of KFA115 (a novel immunomodulatory small molecule, presumed to enhance anti-tumor immunity) as monotherapy and in combination with pembrolizumab. Exclusion criteria include significant cardiac, autoimmune, and interstitial lung diseases, as well as history of severe hypersensitivity to study drugs.
ClinicalTrials.gov ID: NCT05544929
HealthScout AI summary: Adults with advanced unresectable or metastatic melanoma (non-uveal/mucosal), head and neck squamous cell carcinoma, non-small cell lung cancer, triple negative breast cancer, or classical Hodgkin lymphoma who have progressed on prior PD-1/PD-L1 therapy are eligible to receive CTX-8371, an investigational bispecific antibody targeting PD-1 and PD-L1 designed to overcome checkpoint inhibitor resistance, as monotherapy.
ClinicalTrials.gov ID: NCT06150664
HealthScout AI summary: This trial enrolls adults with advanced or metastatic Claudin-1 positive squamous solid tumors (including SqNSCLC, HNSCC, ESCC, or CSCC) who are refractory or intolerant to standard therapies. Patients receive ALE.P02, a CLDN1-targeted antibody-drug conjugate that delivers a tubulin inhibitor selectively to CLDN1-positive tumor cells.
ClinicalTrials.gov ID: NCT06747585
HealthScout AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors expressing CEACAM5—including colorectal, non-small cell lung, or gastric cancer—who have progressed after standard therapies, to receive investigational BMS-986490 (a first-in-class targeted agent for CEACAM5-expressing malignancies) alone or combined with bevacizumab. Key exclusions include prior anti-CEACAM5 therapy or significant pulmonary toxicity.
ClinicalTrials.gov ID: NCT06730750
HealthScout AI summary: This trial enrolls adults with advanced solid tumors, including NSCLC, harboring SMARCA4 (BRG1) alterations who have no standard treatment options and ECOG 0-1, and treats them with LY4050784, an investigational oral selective SMARCA2/BRM ATPase inhibitor targeting cancers with SMARCA4 loss of function.
ClinicalTrials.gov ID: NCT06561685
HealthScout AI summary: Eligible patients have advanced, unresectable, or metastatic solid tumors of multiple types that are refractory to standard therapy and have a tumor accessible for intratumoral injection or biopsy. This trial evaluates the investigational oncolytic immunotherapy VET3-TGI (a vaccinia-derived agent engineered to kill tumor cells and modulate the tumor microenvironment via CXCR3, IL-12, and TGF-β inhibition) given by intratumoral or intravenous administration, alone or with pembrolizumab.
ClinicalTrials.gov ID: NCT06444815